MedTrace Logo

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

NCT05014789 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-01-11

No results posted yet for this study

Summary

The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

Control-IQ technology 2.0

All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor

Sponsors & Collaborators

  • Tandem Diabetes Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Jordan E Pinsker, MD · Tandem Diabetes Care, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-19
Primary Completion
2021-12-20
Completion
2021-12-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014789 on ClinicalTrials.gov